๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Pancreas Cancer
Clinical trial register · China

Pancreas Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 6 Hangzhou 4 Guangzhou 3 Beijing 3 Nanchang 1
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai6 Hangzhou4 Guangzhou3 Beijing3 Nanchang1
All 13 locations
Target enrolment
to

Pancreas Cancer trials in China

18 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC
NCT06913218Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma
Akeso
Phase 1
60
Shanghai
2025-07-22
Recruiting
Construction and Clinical Application of the Immune Map of Pancreatic Cancer Evolution
NCT07034339Immune Evasion, Tumor, Pancreas Cancer
First Affiliated Hospital of Zhejiang University
Observational
1,500
Hangzhou
2025-05-21
Recruiting
Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer
NCT06572813Pancreas Cancer
First Affiliated Hospital of Zhejiang University
Phase 1/2
63
Hangzhou
2024-11-15
Recruiting
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
NCT07433283Tumor, Solid, Lung Cancer, Pancreas Cancer, Thyroid Cancer
Sichuan Enray Pharmaceutical Sciences Company
Phase 1/2
54
Beijing, Hunan, Chongqing, Fuzhou, Haikou, Heilongjiang, Shanghai, Chengdu
2024-11-12
Not yet open
TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor
NCT06619886Solid Tumor, Adult, Lung Adenocarcinoma, Pancreas Cancer, Colorectal Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase EARLY_PHASE1
9
Shanghai
2024-09-24
Not yet open
Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
NCT06531291ESCC, Biliary Tract Cancer, Gastric Cancer, Pancreas Cancer
RenJi Hospital
Phase 2
80
Shanghai
2024-08-10
Recruiting
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
NCT06534762NSCLC, SCLC, Colorectal Cancer, Pancreas Cancer
Zhejiang Provincial People's Hospital
Phase 2
260
Hangzhou
2024-07-15
Recruiting
GPC3/Mesothelin-CAR-ฮณฮดT Cells Against Cancers
NCT06196294Pancreas Cancer, Lung Cancer, Liver Cancer, Mesothelioma
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2024-05-10
Recruiting
Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE)
NCT06277531Biliary Stricture, Bile Duct Cancer, Pancreas Cancer
Peking University Third Hospital
Observational
99
Beijing
2024-03-01
Recruiting
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
NCT06010862Gastric Cancer, Colon Cancer, Pancreas Cancer, Esophagus Cancer
Chongqing Precision Biotech Co., Ltd
Phase 1
36
Nanchang
2023-09-30
Recruiting
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
NCT06050317Pancreas Cancer
Shandong Cancer Hospital and Institute
Phase 2
25
Jinan
2023-08-18
Recruiting
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
NCT06043466Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer
Chongqing Precision Biotech Co., Ltd
Phase 1
30
Hangzhou
2023-08-11
By invitation
Modified vs Conventional Blumgart Anastomosis of LPD for the Effects of Pancreatic Fistula of Periampullary Carcinoma
NCT06076252Ampullary Cancer, Bile Duct Cancer, Pancreas Cancer, Duodenum Cancer
Affiliated Hospital of Guangdong Medical University
Not applicable
150
Zhanjiang
2023-07-01
Recruiting
Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
NCT05779917Pancreas Cancer, CAR-T Cell Therapy, Mesothelin, Solid Tumor, Adult
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2023-03-10
Recruiting
MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer
NCT07045571Pancreatic Neoplasm, Pancreas Cancer
Yingbin Liu, MD, PhD, FACS
Observational
1,000
Shanghai
2022-10-30
Recruiting
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
NCT05187338Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer
Second Affiliated Hospital of Guangzhou Medical University
Phase 1/2
100
Guangzhou
2021-11-01
Recruiting
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
NCT05218889Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreas Cancer, Pancreatic Neoplasms
Chinese PLA General Hospital
Phase 1/2
90
Beijing
2021-08-04
Recruiting
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
NCT03093688Non-small Cell Lung Cancer, Small Cell Lung Cancer, Pancreas Cancer, Hepatocellular Carcinoma
Shanghai Public Health Clinical Center
Phase 1/2
40
Shanghai
2017-03-01
Rows per page Showing 1–18 of 18
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/pancreas-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 18 of those studies listing the condition Pancreas Cancer.

How many Pancreas Cancer trials are recruiting in China?

14 of the 18 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 0 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Pancreas Cancer), 18 studies
PhaseStudiesRecruitingShare
Phase 15427.8%
Phase 1/25527.8%
Observational3316.7%
Phase 23216.7%
Not applicable105.6%
Phase EARLY_PHASE1105.6%

Most active sponsors

Lead sponsors with the most studies (Pancreas Cancer)
Lead sponsorStudiesRecruiting
Second Affiliated Hospital of Guangzhou Medical University33
Chongqing Precision Biotech Co., Ltd22
First Affiliated Hospital of Zhejiang University22
Affiliated Hospital of Guangdong Medical University10
Akeso10
Chinese PLA General Hospital11
Peking University Third Hospital11
RenJi Hospital10
Shandong Cancer Hospital and Institute11
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.